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5-FLUOROURACIL CARDIOTOXICITY
Iskandar M Z, Quasem W, El-Omar M
Manchester Heart Centre, Oxford Road M13 9WL, Manchester, United Kingdom.
ABSTRACT
The increasing prevalence of malignancies in the current population sees increasing
usage of chemotherapy agents, which in itself carries various side effect profiles. We
report a case of 5-fluorouracil  (5-FU) cardiotoxicity in a young gentleman with no
pre-existing cardiac history who was given his first ever dose of 5-FU. Mechanisms of
5-FU cardiotoxicity are varied, but most commonly involves an element of intense
coronary  vasospasm  with  accompanying  transient  global  left ventricular  systolic
dysfunction (LVSD). Apart from cessation of 5-FU, treatment is mainly conservative
and outcomes are good with potential reversibility of LVSD.
INTRODUCTION
Cardiotoxicity following chemotherapy is a rare but important side effect as it carries
a great risk of morbidity and mortality if unrecognized.[ CITATION Kha13 \l 1033 ] 5-
fluorouracil  (5FU)  is  frequently  used as  a  chemotherapy  agent  in  gastrointestinal
malignancies and cardiotoxicity secondary to this is a well-recognized complication
although not often seen in daily clinical practice.[ CITATION Kha13 \l 1033 ] Clinical
presentation in the Emergency Department often mimics acute coronary syndrome
or acute decompensation of  heart  failure.  Recognition of  cardiotoxicity  is  vital  as
correct management will often lead to a good outcome. We report a case of 5-FU
cardiotoxicity in a young gentleman who presented to our cardiology department via
the primary percutaneous coronary intervention (PCI) pathway.
CASE REPORT
A 33  year-old  man was  admitted to  hospital  following  a  1  day-history  of  feeling
generally unwell  following chemotherapy.  He was being treated for  bowel  cancer
which was diagnosed 2 months prior as a poorly differentiated mucinous signet ring
tumour in his proximal descending colon. A staging CT scan staged the tumour as T4
N2 M0 and he had already undergone an extended right hemi-colectomy for the first
part of his treatment. Following this, he commenced chemotherapy and received 5-
fluorouracil  (5FU)  along  with  Oxaliplatin  3  days  prior  to  presentation.  This  was
administered as an infusion via a Hickman line and was his first exposure to 5-FU.
On arrival to hospital he described a feeling of general malaise, shortness of breath,
and atypical  chest pain. However, he did not report any chest pain.  Fifteen years
prior,  he  was  also  treated  for  a  left tibial  osteosarcoma  for  which  he  received
Cisplatin and Doxorubicin combination chemotherapy along with tumour resection
and prosthesis insertion. Cardiac MRI following chemotherapy at the time showed
normal cardiac structure and left ventricular function.
Initial ECG during this presentation did not show any dynamic ischaemic changes. On
clinical examination he was haemodynamically stable, heart sounds were normal and
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chest was clear. Therefore the decision was made to not proceed to primary PCI at
this point and treat him medically for acute coronary syndrome (ACS).
Figure 1 – Initial ECG on presentation.
However after a few hours, the patient started to complain of flu-like symptoms,
myalgia, and rigors. There was chest tightness as well as orthopnoea but he was not
pyrexial. A repeat ECG showed dynamic changes in the form of T wave inversion in
leads  V3  –  V6  and  also  the  inferior  leads.  Another  ECG  10  minutes  later
demonstrated further changes in the form of saddle-shaped ST elevation in leads V4-
V6. Troponin I 8 hours post admission was raised at 109 ng/L (normal lab values 1 –
14 ng/L). Echo demonstrated severely impaired left ventricular systolic dysfunction
(LVSD) with an ejection fraction of 26%. The left ventricle was not dilated and there
was no pericardial effusion or valvular abnormalities. The LVSD was global and there
were no regional wall motion abnormalities (RWMA).
Figure 2 – Second ECG while patient was complaining of chest tightness. Note T wave
changes in leads II, III, aVF as well as V3 – V6
As a result of his ECG changes, raised Troponin and clinical symptoms, the working
diagnosis  at  this  juncture  was  acute  coronary  syndrome  (ACS)  with  a  severely
reduced ejection fraction. He was therefore treated with heart failure medications
consisting of a beta-blocker (Bisoprolol 1.25 mg), ACE inhibitor (Ramipril 1.25 mg)
and mineralocorticoid receptor antagonist (Spironolactone 25 mg) as well  as dual
antiplatelet therapy (Aspirin 75 mg and Clopidogrel 75 mg).
Figure 3 – A further ECG 10 minutes after the second ECG demonstrated saddle
shaped ST elevation in leads V4 – V6
Figure 4 – Echo demonstrating a left ventricular ejection fraction (LVEF) of 26%.
LVESV: Left ventricular end-systolic volume, LVEDV: Left ventricular end-diastolic
volume, SV: systolic volume, MOD A4C: method of discs apical 4-chamber.
The  following  day,  an  angiogram  was  arranged  which  showed  normal  coronary
arteries. All heart failure medications were stopped and he was commenced on a
calcium channel blocker and nitrates. A repeat echocardiogram and cardiac MRI were
also performed after a week and this showed a complete resolution of LV systolic
dysfunction with normal ejection fraction at 61% and a structurally normal heart. The
patient improved and was subsequently discharged home. 
 
    
Figure 1
DISCUSSION
5-FU
5-fluorouracil  is  an  anti-metabolite  from  the  fluoropyrimidine  group  and  is
increasingly popular as a chemotherapy agent in a combined chemotherapy regime
for  gastrointestinal  cancers  or  as  a  neoadjuvant  agent.  Thymidylate  synthase,  a
crucial  enzyme  in  pyrimidine  nucleotide  synthesis  is  inhibited  and  this  leads  to
inhibition of DNA synthesis and repair[ CITATION Shr09 \l 1033 ]. Oncology outcomes
are  good,  with  reports  of  absolute  risk  reduction  in  5-year  mortality  of  5.8% in
resectable gastric cancers when combined with surgical resection as reported in a
meta-analysis  by  Paoletti et  al [  CITATION  Pao10  \l  1033  ]. As  with  all  forms  of
chemotherapy, side effects such as mucositis, diarrhoea, and immunosuppression are
common. Cardiotoxicity is a much rarer event but is more serious due to the risk of
acute coronary syndrome, cardiomyopathy, and direct myocardial damage. Patients
can  also present  with  life-threatening  arrhythmias.[  CITATION Mic12  \l  1033 ] At
present, the rate of symptomatic cardiotoxicity from 5-FU treatment is reported to
be around 1.2 – 4.3% and is more likely to occur with longer infusions compared to
bolus injections. [ CITATION Pol13 \l 1033 ]
 
Mechanisms of toxicity
The exact  mechanism of  cardiotoxicity  is  unclear,  but  several  theories have been
postulated,  primarily  coronary  vasopasm  leading  to  acute  ischaemia,  direct  toxic
effect on the myocardium, and a hypercoagulable state causing a thrombotic event. 
Coronary vasospasm
The  clinical  presentation  is  often  similar  to  acute  coronary  syndrome  (ACS)  with
patients complaining of chest pain or tightness accompanied by a rise in troponin-I or
other  markers  of  myocardial  damage.  ECG  changes  are  often  ischaemic  with  ST
segment  changes.  These  investigations  however  do  not  always  reflect  coronary
artery  disease  (CAD)  as  numerous  case  reports  have  reported  normal  coronary
arteries in these patients on angiography. Coupled with good response to nitrates
and calcium channel blockers as was the case in our patient, this strongly supports
the theory of coronary vasospasm underlying the clinical presentation. 
Thrombotic event
5-FU can also cause direct injury to endothelial cells. A sequelae of this would be
platelet aggregation and ultimately thrombus formation. Despite not having previous
coronary artery disease, a patient can potentially develop endothelial  dysfunction
and  therefore  experience  a  pathophysiological  cascade  of  events  that  leads  to
thrombus  formation[  CITATION Cwi96  \l  1033  ].  Further  evidence  has  also  been
discovered that seems to support a prothrombotic state in these patients. Kuzel et al
administered 5-FU in 10 cancer patients and measured assays for protein C, protein S
and fibrinopeptide A.  There is  a  reduction in  the level  of  protein  C  activity  with
coexisting increase in fibrinopeptide A in these patients which supports activation of
coagulation  [ CITATION Kuz90 \l 1033 ]. A combination of endothelial injury and a
hypercoagulable state unsurprisingly creates a favourable environment for thrombus
formation. 
Direct toxic effect on the myocardium
Another  possibility  is  a  direct  toxic  effect  on  the  myocardium.  Current  literature
reports several different direct toxic effects. Among those that have been seen are
haemorrhagic myocardial infarction, left ventricular hypertrophy with necrosis and
apoptosis  of  the endothelial  cells,  diffuse myocarditis  and sarcoplasmic reticulum
dilatation [ CITATION Mic12 \l 1033 ]. These will more often than not give rise to a
diffuse area of systolic dysfunction seen on echocardiography or functional imaging.
Treatment
Assuming coronary arteries are normal, treatment is usually conservative, aimed at
the underlying coronary vasospasm and resulting left ventricular systolic dysfunction,
which normally recovers. Success rates have been reported to be around 70 – 90%
[ CITATION Mic12 \l 1033 ]. In the case of our patient, conventional treatment with
heart  failure  medications  as  well  as  calcium  channel  blockers  and  nitrates  for
vasospasm proved beneficial. On hindsight, it is difficult to determine with certainty
whether  the  resulting  systolic  dysfunction  would  have  resolved  on  its  own  with
cessation of the chemotherapy agent.
Pre-medication with calcium channel blockers to prevent coronary vasospasm has
not proven to be of benefit as demonstrated by Eskilsson et al in which Verapamil
120 mg three times a day was administered prophylactically [ CITATION Esk90 \l 1033
]. In addition to this, there has been no convincing clinical evidence of the use of any
other agents prophylactically prior to 5-FU administration. Cessation of the drug or
reduction in dose remains the most important step in the management of  these
patients. 
Conclusion 
In  summary,  5-FU cardiotoxicity  is  a  rare  yet  important  side  effect  of  its  use.  Its
efficacy in dealing with gastrointestinal malignancies will ensure it retains its place as
a  favoured chemotherapy  agent  in  this  setting.  Despite  not  having  a  pre-existing
cardiac  history,  patients  can  present  to  the  hospital  with  life  threatening  cardiac
symptoms. Awareness of the various underlying mechanisms of cardiotoxicity will
assist the clinician in directing treatment along with cessation of the drug. Outcomes
are good and the potential reversibility of left ventricular systolic dysfunction in these
patients makes its early recognition even more vital in a clinical setting. 
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